Answers are grounded in this paper and cite their sources.
Gout is a common form of arthritis; however, there are currently no effective therapies available. Ozonated autohemotherapy (O3‑AHT) is a controversial, but successful method of treatment for a number of diseases. The present study is the first pilot study investigating the application of O3‑AHT in patients with hyperuricemia and gout. In total, 10 patients diagnosed with gout were recruited and subjected to O3‑AHT. Self‑reported pain visual analog scale (VAS) scores and creatinine clearance values were evaluated prior to (T0), during (after the fifth session of O3‑AHT treatment; 1‑4 weeks; T1) and following the treatment course (5‑28 weeks; T2). At T1, the creatinine clearance rate of the patients significantly increased from 105.14±35.33 (T0) to 121.45±44.52 ml/min (t=2.165, P=0.062), while the pain VAS score decreased from 5.35±2.78 (T0) to 3.30±2.21 (t=2.004, P=0.076). However, at T2, the creatinine clearance rate decreased slightly to 111.15±36.52 ml/min, and no statistically significant difference was observed from the value at T0 (t=1.723, P=0.123). The pain VAS score further decreased to 2.30±2.66 (t=2.628, P=0.027). In conclusion, O3‑AHT decreased the creatinine clearance rate and the pain VAS scores of patients with hyperuricemia and gout; thus, may be a potential effective therapeutic approach.
No takes yet. Share an insight, caveat, or question.
LI et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: